Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes
GLP-1 RA utilization among US adults with type 2 diabetes has substantially increased, with use in 2021-2022 nearly double that of the period prior to 2020. The higher health care costs associated with taking GLP-1 RAs were largely attributable to high drug costs, of which over 95% were covered by insurance.
Authors
- Jun Wu (ORCID: https://orcid.org/0000-0003-2483-6980)
- Alexandra Pérez (ORCID: https://orcid.org/0000-0003-4543-7460)
- Patrick W. Sullivan (ORCID: https://orcid.org/0009-0003-2783-7177)
Institutions
- Nova Southeastern University (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-09-26
- DOI
- https://doi.org/10.18553/jmcp.2025.31.10.1029
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29